ATyr Pharma Top Management
ATyr Pharma employs about 56 people. The company is managed by 11 executives with a total tenure of roughly 25 years, averaging almost 2.0 years of service per executive, having 5.09 employees per reported executive. Evaluation of ATyr Pharma's management performance can provide insight into the firm performance.
Melissa Ashlock President Vice President - External Scientific Alliances and Human Genetics |
David King President Senior Vice President - Research |
ATyr |
ATyr Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2937) % which means that it has lost $0.2937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5561) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma's management efficiency ratios could be used to measure how well ATyr Pharma manages its routine affairs as well as how well it operates its assets and liabilities.ATyr Pharma Workforce Comparison
ATyr Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,126. ATyr Pharma holds roughly 56.0 in number of employees claiming about 5% of equities under Health Care industry.
ATyr Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ATyr Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ATyr Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ATyr Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Shukla Sanjay over six months ago Acquisition by Shukla Sanjay of 20000 shares of ATyr Pharma at 1.807 subject to Rule 16b-3 | ||
Coughlin Timothy over six months ago Acquisition by Coughlin Timothy of 50000 shares of ATyr Pharma at 1.75 subject to Rule 16b-3 | ||
Clarke John K over six months ago Disposition of 6000 shares by Clarke John K of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over six months ago Acquisition by Sanjay Shukla of 3000 shares of ATyr Pharma at 1.17 subject to Rule 16b-3 | ||
Sanjay Shukla over six months ago Exercise or conversion by Sanjay Shukla of 10375 shares of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over six months ago Acquisition by Sanjay Shukla of 600000 shares of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over a year ago Purchase by Sanjay Shukla of 1422 shares of ATyr Pharma | ||
Sanjay Shukla over a year ago Purchase by Sanjay Shukla of 15000 shares of ATyr Pharma |
ATyr Pharma Notable Stakeholders
An ATyr Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ATyr Pharma often face trade-offs trying to please all of them. ATyr Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ATyr Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MS MD | CEO President | Profile | |
Melissa Ashlock | Vice President - External Scientific Alliances and Human Genetics | Profile | |
David King | Senior Vice President - Research | Profile | |
Danielle Campbell | VP Resource | Profile | |
XiangLei Yang | Founder | Profile | |
Ying Buechler | Executive Manufacturing | Profile | |
Jill Broadfoot | Chief Officer | Profile | |
Ashlee Dunston | Director Communications | Profile | |
Peter Villiger | Vice Development | Profile | |
Leslie Nangle | Vice Research | Profile | |
Nancy Krueger | General Secretary | Profile |
About ATyr Pharma Management Performance
The success or failure of an entity such as ATyr Pharma often depends on how effective the management is. ATyr Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ATyr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ATyr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company was incorporated in 2005 and is headquartered in San Diego, California. Atyr Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.
Please note, the presentation of ATyr Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ATyr Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ATyr Pharma's management manipulating its earnings.
ATyr Pharma Workforce Analysis
Traditionally, organizations such as ATyr Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ATyr Pharma within its industry.ATyr Pharma Manpower Efficiency
Return on ATyr Pharma Manpower
Revenue Per Employee | 6.3K | |
Revenue Per Executive | 32.1K | |
Net Loss Per Employee | 899.8K | |
Net Loss Per Executive | 4.6M | |
Working Capital Per Employee | 1.5M | |
Working Capital Per Executive | 7.9M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |